Steven Cohen Terns Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 160,725 shares of TERN stock, worth $572,181. This represents 0.0% of its overall portfolio holdings.

Number of Shares

160,725

Previous 1,251,841 87.16%

Holding current value

$572,181

Previous $6.99 Million 93.66%

% of portfolio

0.0%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.76 - $5.79 $3.01 Million - $6.32 Million	-1,091,116 Reduced 87.16%	160,725 $443,000
Q4 2024 Feb 14, 2025	SELL	$5.53 - $8.36 $8.05 Million - $12.2 Million	-1,455,674 Reduced 53.76%	1,251,841 $6.99 Million
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $111,232 - $185,101	17,139 Added 0.64%	2,707,515 $22.6 Million
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $2.13 Million - $3.85 Million	469,176 Added 21.12%	2,690,376 $18.3 Million
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $10.8 Million - $18.2 Million	2,221,200 New	2,221,200 $14.6 Million
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $2.68 Million - $4.88 Million	571,265 New	571,265 $2.87 Million
Q1 2023 May 15, 2023	BUY	$7.91 - $12.0 $3.13 Million - $4.75 Million	395,598 Added 169.42%	629,098 $7.45 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $1.08 Million - $2.38 Million	233,500 New	233,500 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$1.5 - $3.0 $566,140 - $1.13 Million	377,427 Added 307.92%	500,000 $1.24 Million
Q1 2022 May 16, 2022	BUY	$2.83 - $6.7 $346,881 - $821,239	122,573 New	122,573 $364,000

Others Institutions Holding TERN

# of Institutions

143

Shares Held

84.5M

Call Options Held

256K

Put Options Held

133K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $134M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account